AS 1842856

Product Description

AS 1842856 is a potent and selective Foxo1 inhibitor (IC₅₀ values are 33 nM at Foxo1 and >1 μM at Foxo3a and Foxo4); decreases Foxo-mediated promoter activity by 70%, 20% and 3% at Foxo1, Foxo4 and Foxo3, respectively. Regulates gluconeogenesis both in vitro and in vivo. Attenuates fasting plasma glucose level in diabetic db/db mice. Also suppresses autophagy, adipocyte differentiation and soluble guanylyl cyclase expression. Also inhibits STAT3 signaling in NSCLC. Orally bioavailable.

Solubility

Preparing Stock Solutions for AS 1842856

The following data is based on the product molecular weight 347.39

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.05 mM	57.57 mL	287.86 mL	575.72 mL
0.25 mM	11.51 mL	57.57 mL	115.14 mL
0.5 mM	5.76 mL	28.79 mL	57.57 mL
2.5 mM	1.15 mL	5.76 mL	11.51 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Liu FoxO1 antagonist suppresses autophagy and lipid droplet growth in adipocytes. Cell Cycle 2016 PMID: 27260854
• Galley Antagonism of forkhead box subclass O transcription factors elicits loss of soluble guanylyl cyclase expression. Mol.Pharmacol. 2019 PMID: 30988014
• Nagashima Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol.Pharmacol. 2010 PMID: 20736318